ARTICLE | Company News
FDA approves Velcade for first-line MCL
October 10, 2014 2:29 AM UTC
FDA approved an sNDA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to expand the label of Velcade bortezomib to include first-line mantle cell lymphoma (MCL). The pharma said Velcade is the first treatment to be approved in the U.S. for previously untreated MCL patients.
The small molecule dipeptide boronic acid proteasome inhibitor is already approved in the U.S. to treat relapsed/refractory MCL and multiple myeloma. ...